Scienture Holdings Inc has announced a strategic collaboration with Blink Rx to expand nationwide access to Arbli, a newly approved oral liquid formulation of losartan potassium.
Arbli is the first US FDA-approved, ready-to-use oral suspension of losartan, designed for patients who need or prefer liquid medications.
What This Collaboration Means?
Under the partnership, Arbli will be made available through the BlinkRx patient access platform starting Q1 2026.
BlinkRx supports the full prescription journey by:
- Reducing administrative delays
- Improving therapy initiation
- Supporting long-term adherence
According to BlinkRx data:
- 52% more patients start therapy
- Patients stay on treatment 40% longer
Addressing a Large Market and an Unmet Need
Losartan is one of the most widely prescribed blood pressure medicines in the US.
According to IQVIA (MAT September 2025):
- The US losartan market is worth $245 million annually
- Over 71 million prescriptions are written each year
Despite its widespread use, liquid formulations have remained limited. Arbli fills this gap without requiring compounding.
Why Arbli Is Different?
Arbli is a proprietary liquid formulation with several patient-friendly advantages:
- Ready-to-use oral suspension
- No compounding required
- Reduced dosing volume
- Room-temperature storage
- 24-month shelf life
- Peppermint-flavored
It comes in a 165 mL bottle and does not require refrigeration.
Approved Indications
Arbli is approved by the US FDA for:
- Treatment of hypertension in adults and children over six years
- Reducing stroke risk in patients with hypertension and left ventricular hypertrophy
- Treating diabetic nephropathy in certain patients with type 2 diabetes
Lowering blood pressure helps reduce the risk of heart attacks and strokes.
Leadership Perspectives
Narasimhan Mani, president and co-CEO of Scienture, said Arbli addresses a real patient need by offering a convenient liquid option supported by BlinkRx’s access platform.
Shankar Hariharan, executive chairman and co-CEO of Scienture, highlighted the shared focus on affordability, access, and patient-centered care.
Geoffrey Chaiken, CEO of Blink Health, noted that ready-to-use liquid losartan helps patients start therapy faster and remain supported throughout treatment.
Strong IP and Regulatory Position
Arbli is protected by two issued US patents, both listed in the FDA Orange Book.
As an FDA-approved product, it ensures:
- Consistent quality
- Accurate dosing
- Reduced risks compared to compounded alternatives
The Bigger Picture
With Arbli and BlinkRx working together, Scienture is positioning itself to improve access to essential hypertension therapy while unlocking a significant commercial opportunity.
For patients who struggle with tablets, this collaboration could make long-term blood pressure management simpler and more reliable.
